Prevalence and Factors Associated With Liver Test Abnormalities Among Human Immunodeficiency Virus-Infected Persons

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 2, 2010, Pages 183-191

  Crum Cianflone, Nancy ^a,b   Collins, Gary ^c   Medina, Sheila ^a,b   Asher, Dean ^a   Campin, Richard ^a   Bavaro, Mary ^a,b   Hale, Braden ^a,b   Hames, Charles ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; PARACETAMOL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALCOHOL ABUSE; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; FEMALE; HEMOCHROMATOSIS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE;

ADULT; COMORBIDITY; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREVALENCE;

EID: 75349083385     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.09.025     Document Type: Article

References (30)

1. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
2. Palella Jr. F.J., Baker R.K., Moorman A.C., et al., HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43 (2006) 27-34
3. Soriano V., Martín-Carbonero L., García-Samaniego J., et al. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 33 (2001) 1793-1795
4. Puoti M., Spinetti A., Ghezzi A., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 (2000) 211-217
5. Weber R., Sabin C.A., Friis-Møller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 (2006) 1632-1641
6. Ioannou G.N., Boyko E.J., Lee S.P., et al. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 101 (2006) 76-82
7. Pol S., Lebray P., and Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 38 (2004) S65-S72
8. Bonacini M. Hepatobiliary complications in patients with human immunodeficiency virus infection. Am J Med 92 (1992) 404-411
9. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
10. Guaraldi G., Squillace N., Stentarelli C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 47 (2008) 250-257
11. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44 (2006) S132-S139
12. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
13. In: Rumack C.M., Wilson S., Charboneau W.J., et al. (Eds). Diagnostic ultrasound. 3rd ed. Volume 1 (2005), Elsevier Mosby, St. Louis
14. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
15. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 6 (1998) 51S-209S
16. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
17. Sterling R.K., Chiu S., Snider K., et al. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 53 (2008) 1375-1382
18. Centers for Disease Control and Prevention. U.S. obesity trends. Trends by state 1985-2008. http://www.cdc.gov/obesity/data/trends.html Accessed: August 6, 2009
19. Joseph A.E., Saverymuttu S.H., al-Sam S., et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43 (1991) 26-31
20. Hamaguchi M., Kojima T., Takeda N., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
21. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
22. Spengler U., Lichterfeld M., and Rockstroh J.K. Antiretroviral drug toxicity-a challenge for the hepatologist?. J Hepatol 36 (2002) 283-294
23. Savès M., Vandentorren S., Daucourt V., et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). AIDS 17 (1999) F115-F121
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (November 3, 2008). http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 1-139. Accessed: February 1, 2009
25. Bruno R., Sacchi P., and Filice G. Mitochondrial toxicity in HIV-HCV coinfection: it depends on the choice of antiretroviral drugs?. Hepatology 35 (2002) 500-501
26. Papatheodoridis G.V., Goulis J., Christodoulou D., et al. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol 19 (2007) 281-287
27. Lazo M., Selvin E., and Clark J.M. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 148 (2008) 348-352
28. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
29. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-9
30. Pantsari M.W., and Harrison S.A. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol 40 (2006) 633-635